On May 1, 2026, State Council Order No. 818 “Regulations on the Management of Clinical Research and Clinical Translation Application of New Biomedical Technologies” officially came
In the first half of 2026, Chinese innovative drugs went global with remarkable results: BD transactions exceeded $100 billion, and leading companies such as CSPC, Hengrui,
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible
The inventiveness of crystal type patents has never been judged by “whether a new crystal mold has been made,” but rather on “whether this new mold
On October 26, the second page of People’s Daily published a report titled “Intellectual Property Is the Confidence for Sustained R&D Investment,” presenting a macro dataline:
Around October 20, a group of domestic innovative pharmaceutical companies were the first to disclose their performance forecasts for the first three quarters of 2026:
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible
In recent years, gene therapy has entered a period of rapid development. With the world’s first CRISPR therapy approved for market and several AAV gene drugs
On October 14, the National Intellectual Property Administration and the General Administration of Customs jointly issued the “Opinions on Strengthening Collaborative Protection of Intellectual Property.” The
From 2025 to 2030, nearly 70 flagship drug patents in the global pharmaceutical industry will expire, facing an annual sales loss of approximately $236 billion. Large